My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no. Compounded GLP‑1s are generally not the best first option because they’re unapproved, higher‑risk, and often not cheaper or covered by insurance. There are safer, legitimate routes to pursue first.

Why compounded GLP‑1s are risky or problematic

• Not FDA‑approved: compounded versions haven’t gone through FDA testing for purity, potency, stability or safety for weight loss.
• Quality/safety concerns: compounding errors, contamination, wrong dose and sterility lapses have been reported.
• No insurance coverage: you’ll likely pay out‑of‑pocket and get no reimbursement.
• Limited evidence: efficacy and long‑term safety of compounded formulations are unproven.
• Legal/ethical issues: some compounding for commercially available drugs may violate regulations in some states.

Safer alternatives to try first

1. Appeal the denial
   • Ask your prescriber to submit a peer‑to‑peer review or a letter of medical necessity to your insurer. Provide BMI, comorbidities, prior weight‑loss attempts, and evidence (clinical trial data) showing benefit.
2. Manufacturer assistance and savings
   • Novo Nordisk Wegovy savings card or patient support (for commercially insured) may reduce copays; contact Novo Nordisk or your prescriber’s office.
   • Eli Lilly offers patient assistance (LillyCares) and support programs for tirzepatide (Zepbound/Mounjaro); check eligibility.
3. Consider other FDA‑approved prescription options
   • Zepbound (tirzepatide) — approved for weight management (if available and covered, often effective).
   • Saxenda (liraglutide) — FDA‑approved for weight loss (daily injection).
   • Qsymia (phentermine/topiramate) or Contrave (bupropion/naltrexone) — oral prescription options.
   • Orlistat (Xenical prescription or Alli OTC) — modest weight loss, different side‑effect profile.
     Talk with your clinician about medical suitability and insurance coverage for these.
4. Off‑label but supervised options
   • Ozempic (semaglutide) is approved for diabetes and often used off‑label for weight loss; some patients find it easier to get coverage if diabetes is present, but insurers may still deny. This should only be done under clinician supervision.
5. Clinical programs and bariatric options
   • Weight‑management clinics and multidisciplinary programs can combine medication, nutrition, behavior therapy and may help with insurance navigation. If BMI and comorbidities meet criteria, bariatric surgery is an evidence‑based option with long‑term data.

If you’re still considering a compounded product

• Only use a state‑licensed compounding pharmacy with strong sterility controls and third‑party accreditation; ask for proof (USP compliance, licensure).
• Ask the pharmacy for Certificates of Analysis, batch testing, and sterility/expiry data.
• Understand you will pay out‑of‑pocket, and your prescriber should monitor you closely (labs, adverse effects).
• Know the legal/regulatory gray area — some insurers and clinicians refuse to support compounded versions.

What I recommend now

• Ask your prescriber to file an appeal/peer‑to‑peer review right away. I can help draft a sample appeal letter or list documentation to submit.
• Call the drug manufacturer’s patient support (Novo Nordisk for Wegovy; Lilly for tirzepatide) to ask about savings programs or patient assistance eligibility.
• If you want, tell me whether you have Medicare, Medicaid, or commercial insurance and whether you have diabetes or other weight‑related conditions — I can give more targeted next steps and draft an appeal template.